Psilocybin Reduces OCD Symptoms

Psilocybin Reduces OCD Symptoms There’s a fascinating ut that’s adding to mounting evidence that psilocybin is one of the most effective treatments for OCD. Published in Comprehensive Psychiatry, researchers led by Luca Pellegrini from the University of Hertfordshire and Imperial College London tried something different. They gave people with OCDa moderate dose of psilocybin instead of the higher doses we usually hear about.And it worked.

The Problem with Going Big

Most psilocybin research involves doses around 25mg that launch you into a full-blown mystical experience. But if you think about it, that’s a tough sell for someone with OCD. These are people who often struggle with a deep fear of losing control. Asking them to surrender to an intense psychedelic journey is like asking someone with a fear of heights to go skydiving.

So Pellegrini’s team asked a smarter question: what if you could get the benefits without the overwhelming trip?

The Sweet Spot

They tested this with 19 adults who had moderate to severe OCD. The design was straightforward. Everyone got a 1mg dose first (basically a placebo), then four weeks later, a 10mg dose.

One week after the 10mg dose, participants showed significant improvement on the Yale-Brown Obsessive Compulsive Scale – the gold standard for measuring OCD symptoms. The effect was large enough to matter clinically, not just statistically.

But the improvement was almost entirely in compulsions, not obsessions. So people found it easier to resist doing the rituals, even though the intrusive thoughts were still mostly there. It’s like psilocybin allowed people to break the behavioural loop without necessarily affecting the mental one.

Building on a Solid Foundation

This isn’t the first time scientists have explored psilocybin for OCD, but it’s part of a growing body of evidence that’s becoming harder to ignore.

The earliest work dates back to 2006, when a sof just 9 patients found that multiple doses of psilocybin led to acute symptom reductions ranging from 23% to 100% on the YBOCS scale. Despite the tiny sample size, it was safe and showed enough promise to inspire further research.

More recently, we’ve seen some compelling animal research. A 2found that a single dose of psilocybin (or even whole mushroom extract) produced long-lasting reductions in OCD-like excessive grooming behaviour in mice.

And then there’s the ongoing which is using a more rigorous placebo-controlled design. Earlysuggest that a single dose of 0.25 mg/kg of psilocybin, paired with non-directive support, effectively reduces OCD symptoms compared to an active placebo (niacin).

What Pellegrini’s work adds to this picture is the sweet spot. A dose high enough to work but low enough to avoid overwhelming someone who’s already struggling with control.